Technology
Emerging Growth Technologies
(CTUM-OTC)

Consortium Service Management Group, Inc.




Donald S. Robbins
President and
Chief Executive Officer

Interview conducted by:
Lynn Fosse
Senior Editor

CEOCFOinterviews.com
August 2003

Consortium Service Management Group, Inc. (CTUM-OTC) has invested heavily and formed strong relationships in a portfolio of state of the art technologies suitable for US and international niche markets. CSMG has been instrumental in working with Ukraine Scientific, Space, Electronics, Defense, Agriculture, Medical Institutes and Research Clinics in identifying advanced technologies and financing the completion of research and development (R & D) of these technologies. Through these activities CSMG has secured ownership and exclusive world rights for several cutting edge technologies including medical devices, environment related and other high tech niche market products. Their exclusive rights include patents, licensing, manufacture, marketing and distribution. In 2000 CSMG began introducing these products to the US and International markets.  CSMG’s corporate objectives are first focused on three areas in the near future for continued development, manufacture and marketing of their current portfolio of technologies including Live Biological Tissue Bonding Platform Technology, CO-2 Separator for landfill gas and Anaerobic Animal Waste Processing Plants. Second, CSMG will continue to evaluate and enlarge its sphere of portfolio products and take in a number of new technologies in the welding, oil and gas and medical areas such as their expandable containers.   Third, CSMG plans continued growth of the United Engineering Joint Stock Company. UEC was founded in 1993 between CSMG as the Foreign Investor and largest shareholder and by the State Property Fund of Ukraine along with 14 of Ukraine's largest Defense Contractors and Enterprises. UEC is working in the area of ICBM dismantlement under the START Treaties and defense conversion projects. UEC has played a key role in the development and engineering design of the Anaerobic Animal Waste Technology owed by CSMG.   Biological tissue bonding technology is a major focus for Consortium. According to Mr. Donald Robbins, President and CEO of CSMG, “We have been developing biological tissue bonding technology since 1996 and the Ukrainians have been working with it before that. What it does is reconnect human tissue without the use of staples, glues, sealants, or sutures. One is able to have surgery on certain organs of the body where the organs are be reconnected without having foreign matter left in the body. This is done using a smokeless radio frequency welding device. Unlike the other radio frequency bonding and welding technologies, our people have learned how to control the heat so there is no necrosis or charring of the tissue. This allows the tissue once it is reconnected to heal quickly and quicker than conventional methods.”   Describing the next steps in the process for CSMG, Mr. Robbins states, “We own the technology and patents and have spent a number of years developing the various surgical procedures. We formed a company called Live Tissue Connect Inc. (LTC), which now holds the technology and are in the process of finding a medical industry CEO to head that company.  From that point on, Live Tissue Connect Inc. will take over the tissue bonding technology and we will take the technology into the world market and start regulatory processes in various countries. Depending on which country you are in and what type of procedure you go through, this could be a process of a few months or 2 to 3 years. We are already approved in the Ukraine for manufacturing and distribution. In some countries, it will take longer than other countries.” Concerning the issue of funding, Mr. Robbins explains, “We funded most of these projects internally but that will change for the commercialization. We will go out into the market place and raise capital, either through private placements, IPO’s or something of that nature. We have been very fortunate that we have had investors that have worked with us for a number of years and who have helped us fund these projects internally.” Asked what potential investors should know, Mr. Robbins tells us, “The tissue bonding technology has been referred to as the Holy Grail of the surgery industry. We would not want to speculate on how long it will take to get it into the mainstream marketplace of the western world but we are moving forward with plans to begin regulatory work in the US and International markets. Today we have done over a thousand successful human surgeries and we are currently running at the rate of 80 to 100 new surgeries per month. We are constantly expanding into different types of procedures for different types of organs. The procedures so far have involved the bonding and reconnecting of incised or separated human tissues in the following body areas - nasal septum, neurosurgery, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, fallopian tube, ovary and testicles - while restoring the normal function of the body organ or tissue. Surgeons tell us that they are able to reduce the amount of surgery time. The healing is, in their opinion, faster and there is very little scar tissue that you can see with the naked eye. In most instances where it is used, we get a leak-proof bond so there is no leakage.”

Instant Access:
To find out more about: Consortium Service Management Group, Inc. (CTUM) you may order the complete text of our interview. To view a copy of this highly informative interview, left click here: ViewCTUM

disclaimer